Pressmeddelande

AcouSort selected for participation in Global Bio-India organized by the Indian Ministry of Science & Technology

AcouSort has been selected for full sponsorship by the Indian Department of Biotechnology (DBT), Ministry of Science & Technology, for participation in Global Bio-India 2024, which will be held in New Delhi, India, September 12-14, 2024.

The Indian Life Science market is vibrant and has shown a significant growth over the last years. Participation in Global Bio-India 2024 provides AcouSort with a fantastic opportunity to meet with Indian diagnostic companies to showcase the capabilities of AcouPlasmaOptical and its potential in various diagnostic settings. The conference will also provide excellent opportunities for AcouSort to meet with Indian cell therapy and flow cytometry companies – two areas where AcouSort has seen a rapid increase in international interest in acoustofluidics over the past couple of years.

The sponsorship comprises travel expenses for two AcouSort representatives, accommodation in India, exhibitor booth, meeting set-ups, as well as pitching opportunities.

“Being selected for full sponsorship in Global Bio-India 2024 is a genuine honor for AcouSort. The Indian bio-tech market is evolving rapidly, and it would be fantastic for us to be part of this thrilling development. Our successful collaboration within point of care diagnostics and a record-high number of ongoing collaborations with industry and academia have put AcouSort in a favorable position, which we hope to expand to the Indian continent,” says Agnes Michanek, Commercial Director at AcouSort.

ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

Beställ vårt nyhetsbrev — inget användarkonto krävs!